Back
Return
Biography
Marie-Helene Saint-Hilaire

Dr. Marie-Helene Saint-Hilaire

Department of Neurology

Boston University Medical Center, USA


Email: neuromsh@bu.edu


Qualifications

1987-1988 Fellowship in Parkinson’s Disease, Boston University School of Medicine

1986-1987 Fellowship in extra-pyramidal disorders, Columbia Presbyterian Hospital

1985 EEG Fellowship, Notre Dame Hospital, Montreal

1984-1985 EEG Fellowship, Montreal Neurological Institute

1981-1984 Residency in Neurology, Montreal Neurological Institute

1980-1981 Residency in Internal Medicine, Hôpital Saint-Luc, Montreal

1980 M.D., University of Montreal

1975 B.A., Biology and Biochemistry, College Marie de France, Montreal


Publications (selected)

  1. Hohler AD, Tsao JM, Katz DI, Dipiero TJ, Hehl CL, Leonard A, Allen V, Gardner M, Phenix H, Saint-Hilaire M, Ellis T. Effectiveness of an Inpatient  Movement Disorders  Program  for Patients with Atypical parkinsonism.Parkinson’s Disease. 2012; 2012:871974. Epub 2011 Nov 10. PMID: 22135763.
  2. J. -M. Lee, E. M. Ramos,J.-H. Lee, T. Gillis,J.S. Mysore, M. R. Hayden, S. C. Warby, P. Morrison, M. Nance, C.A. Ross, R.L. Margolis, F. Squitieri, S. Orobello, S. Di Donato, E. Gomez-Tortosa, C. Ayuso, O. Suchowersky, R. J. A. Trent, E. McCusker, A. Novelletto, M. Frontali, R. Jones, T. Ashizawa, S. Frank, M. H. Saint-Hilaire, S. M. Hersch, H. D. Rosas, D. Lucente, M. B. Harrison, A. Zanko, R. K. Abramson, K. Marder, J. Sequeiros, J. S. Paulsen, G. B. Landwehrmeyer, R. H. Myers, M. E. MacDonald, and J. F. Gusella. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion Neurology March 6, 2012, 78: 690-695.
  3. Hohler AD, Amariei DE, Katz DI, DePiero TJ, Allen VB, Boyle S,  Phenix HA, De Angelis TA, Geibel CD, Smith KM, Saint-Hilaire MH, Ellis T. Treating Orthostatic Hypotension in Patients with Parkinson’s Disease and Atypical Parkinsonism  Improves Function.Journal of  Parkinson’s Disease. August 22, 2012. 10.3233/JPD-2012-012101.
  4. Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.Hum Genet. 2012 , 131(12): 1833-40.
  5. Ji-Hyun Lee, Jong-Min Lee, Eliana Marisa Ramos, Tammy Gillis, Jayalakshmi S.Mysore, Shotaro Kishikawa, Tiffany Hadzi, Audrey E. Hendricks, Michael R. Hayden, Patrick J. Morrison, Martha Nance, Christopher A. Ross, Russell L. Margolis, Ferdinando Squitieri, Cinzia Gellera, Estrella Gomez-Tortosa, Carmen Ayuso, Oksana, Suchowersky, Ronald J. Trent, Elizabeth McCusker, Andrea Novelletto, Marina Frontali, Randi Jones, Tetsuo Ashizawa, Samuel Frank, Marie-Helene Saint-Hilaire, Steven M. Hersch, Herminia D. Rosas, Diane Lucente, Madaline B. Harrison, Andrea Zankoa, Ruth K. Abramson, Karen Marder, Jorge Sequeiros, G. Bernhard Landwehrmeyer on behalf of the Registry Study of the European Huntington's Disease Network, Ira Shoulson on behalf of the Huntington Study Group COHORT project, Richard H. Myers, Marcy E. MacDonald, James F. Gusella. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington’s disease,Biochemical and Biophysical Research Communications. 2012, 424404-408.
  6. Zhang R, Spengler DC, Saint-Hilaire MH, Hohler AD. Association of adverse effects with Monoamine Oxidase type B Inhibitor and Catechol-O- Methyl Transferase Inhibitor Combination Therapy In Parkinson’s Disease Patients.Advances in Parkinson’s Disease. 1:5-10,2012.
  7. Roy S, Cole B, Gilmore D, De Luca C, Thomas C, Saint-Hilaire M, Syed N. High Resolution Tracking of Motor Disorders In Parkinson’s Disease during Unconstrained Activity. Mov. Disord 2013,28:1080-1087.doi:10.1002/mds.25391.
  8. Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, Mc Cusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME. Candidate Glutamatergic and Dopaminergic Pathway Gene Variants do not influence Huntington’s Disease Motor Onset. Neurogenetics. 2013, 14:173-179 doi: 10.1007/s10048-013-0364-y.
  9. Ellis T, Latham NK, De Angelis TR, Thomas CA, Saint-Hilaire M, Bickmore T. Feasibility of a Virtual Exercise Coach to Promote Walking in Community-Dwelling Persons with Parkinson Disease.American Journal of Physical Medicine & Rehabilitation. June 2013-Vol 92(6): 472-485.
  10. Saint-Hilaire M, Ellis T. A Prescription for Physical Therapy and Exercise.Advances in Parkinson Disease 2013, 2:118-120 doi:10.4236/apd.2013.24023.
  11. Saint-Hilaire M. Occupational therapy for Parkinson's disease: increasing awareness.Lancet Neurol. 2014 Jun; 13(6):527-9. PMID: 2472606.
  12. Tickle-Degnen L, Saint-Hilaire M, Thomas CA, Habermann B, Sprague Martinez LS,  Terrin N, Noubary F, Naumova EN. Emergence and evolution of social self-management of Parkinson¿s disease: study protocol for a 3-year prospective cohort study.BMC Neurology, May 2014, 14:95 doi: 10.1186/1471-2377-14-95.
  13. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM, (Site Investigator). A 12-Week, Placebo-Controlled Study (6002-US-006) of Istradefylline in Parkinson Disease.Neurology, 2008; 70: 2233-2240.
  14. Chirieac MC, Shinaman A, Shoulson I and The Huntington Study Group COHORT Investigators. COHORT: A snapshot of Baseline Characterisitcs. Neurotherapeutics 2008: 5(2): 365.
  15. Kayson EP and the Huntington Study Group PHAROS Investigators. Five years of Monitoring the Safety and Feasibility of PHAROS (Prospective Huntington At Risk Observational Study).Neurotherapeutics 2008; 5(2): 366.
  16. Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K, and the Huntington Study Group PHAROS Investigators. Influence of Insurance on the Decision to Pursue genetic Testing in Individuals at Risk for Huntington Disease. Neurotherapeutics 2008; 5(2): 368.
  17. Quaid K, Sims S, Swenson M, Harrison J, Moskowitz C, Stepanov N, Suter G, Westphal B, and the Huntington Study Group PHAROS Investigators. Living at Risk: Concealing Risk and Preserving Hope in Huntington Disease. Neurotherapeutics 2008; 5(2): 368-369.
  18. Ravina B, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern W, Fahn S, Goetz C, Grate S,  Kurlan R, Lang A, Marek K, Kieburtz K, Oakes D, Elliot R, Shoulson I, and the Parkinson Study Group LABS-PD Investigators. A Longitudinal Program for Biomarker Development In Parkinson’s Disease: A Feasibility Study. Movement  Disorders, Vol 24, No. 14, 2009: 2081-2090.
  19. Karen Marder MD MPH, Hongwei Zhao PhD, Croline M. Tanner MD PhD, David Oakes PhD Ira Shoulson MD and the Huntington Study Group PHAROS Investigators. Assessment of dietary intake among adults at risk for Huntington disease: Analysis of PHAROS research participants.Neurology,2009, vol 73, No 5: 385-392.
  20. Gross RE, Watts RL, Hauser RA, Bakay RAE, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R, and the Spheramine Investigational Group. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease: a double –blind, randomised, controlled trial.Lancet Neurology, 2011, Vol 10, No 6: 509-519.
  21. Quaid K, Swenson M, Sims S, Harrison J , Moskowitz C,  Stepanov N, Suter GW, Westphal BJ  for the Huntington Study Group Investigators and Coordinators. What were you thinking? Individuals at risk for Huntington disease Talk about Having children. Neurotherapeutics 2011: Vol 8 (1): 136-7.
  22. Latourelle JC, Hendricks AE, Pankratz N, Wilk JB, Halter C, Nichols WC, Gusella JF, Destefano AL, Myers RH, Foroud T, and the PSG-Progeni  GenePD Investigators, Coordinators, and Molecular Genetic Laboratories. Genomewide linkage Study of Modifiers of LRRK2-Related Parkinson’s Disease.Movement  Disorders, 2011, vol 26, No 11: 2039-44.
  23. Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, Halter C, Doheny KF, Gusella JF, Nichols WC, Myers RH, Foroud T, DeStefano AL; PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Copy number variation in familial Parkinson disease. PLoS, 6(8): e20988. Epub, 2011.
  24. Parkinson Study Group. Phase II Safety, Tolerability, and Dose Selection Study of Isradipine as a Potential Disease-Modifying Intervention in Early Parkinson’Disease (STEADY-PD). Movement Disorders 2013, vol 28, No 13: 1823-1831, DOI: 10.1002/mds.25639.
  25. The Parkinson Study Group SURE-PD Investigators. Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurol. doi:10.1001/jamaneurol.2013.5528.


Profile Details

http://www.bumc.bu.edu/neurology/clinicalfaculty/hilaire/


Last Updated: 2014-09-26